Workflow
回调获资金净流入,创新药ETF天弘(517380)连续两日“吸金”,最新基金份额创历史新高
2 1 Shi Ji Jing Ji Bao Dao·2025-06-06 01:39

Group 1 - The Tianhong Innovation Drug ETF (517380) experienced a decline of 1.68% on June 5, yet it attracted a net inflow of 6.45 million yuan, marking the second consecutive day of net inflows, totaling over 18.2 million yuan [1] - As of the latest close, the fund's shares reached a historical high of 668 million [1] - The ETF recorded a single-day trading volume of 25.09 million yuan, the highest since April 2023 [1] Group 2 - Aijian Securities expressed optimism regarding the trend of Chinese innovative drugs entering global markets, highlighting that the recent ASCO conference showcased significant research achievements [2] - The Chinese pharmaceutical industry is positioned in the global first tier for ADC, bispecific antibodies, and cell therapy, with clear advantages in R&D and production costs [2] - The increasing recognition and influence of Chinese innovative drugs in the global market is expected to accelerate the trend of innovation going abroad, creating a positive feedback loop [2]